Qscreen Ai Inc. · CSE:QAI
Qscreen Ai — Predictmedix AI — Investor Presentation (February 2025)
12 slides from Qscreen Ai's investor presentation, February 2025
Slide 1: Empowering Health Management with AI: SmartHealth AI Stations
AI Empowering Health Management with AI: SmartHealth AI Stations P R ED I C TM E DI X . C O M C SE : PM ED O TC : PM ED F FRA : 3QP
Slide 2: Predictmedix AI Overview
Predictmedix AI Overview Predictmedix AI is an emerging provider of rapid health screening solutions for Predictmedix AI healthcare and organizations where safety is a top priority. The Company’s SmartHealth AI Stations– powered by a proprietary artificial intelligence (AI) – use multispectral CSE:
Slide 3: Executive Summary
Executive Summary Predictmedix AI has solidified its position as a leader in AI technology for healthcare. Our breakthroughs in non-invasive health screening detection have set new standards in the industry. Having recently onboarded two distributors with a combined track record of over $1.2 billion
Slide 4: Market Opportunity
Market Opportunity AI-driven health management and workplace safety sectors are rapidly growing due to technological advancements and increasing demand. AI’s role in Health Management The market is valued at USD 20.9 billion in 2024, projected to reach USD 164.16 billion by 2030. Drivers for this ar
Slide 5: Introducing the SmartHealth AI Station
Introducing the SmartHealth AI Station Predictmedix AI’s SmartHealth is a contactless and non-invasive mechanism of data collection using a multispectral thermal imaging camera along with RGB imagery that detect various biological conditions such as body temperature, heart rate, respiration rate, bo
Slide 6: Key Applications
Key Applications SmartHealth AI Stations have been used successfully in numerous applications. Our key interests are: • Health Facilities • Corporate Offices (Workplace Wellness) • Public Venues & Events • Educational Institutions • Government Institutions These applications highlight the versatilit
Slide 7: Clinical Validation and Global Reach
CLINICAL VALIDATION AND GLOBAL REAC H • Clinical Studies and Validations: Our technology underwent rigorous clinical testing at various locations, including MGM Hospital and in Indonesia with a substantial participant pool, showcasing our commitment to evidence-based solutions. • Implementation in H
Slide 8: Intellectual Property Portfolio
Intellectual Property Portfolio Protecting our Technology in Key Global markets U.S. PATENTS have been filed for Impairment, Infectious 7 Diseases, and Health Management Screening. Additionally, USPTO granted Predictmedix its patent for Impairment Screening C SE : PM ED O TC : PM ED F
Slide 9: Successful Peer-reviewed Publications
Technology Validation Clinical Validation and peer-reviewed medical journals 4 Successful Peer- reviewed publications C SE : PM ED O TC : PM ED F
Slide 10: Board of Directors
Board of Directors Sheldon Kales David Goodman Dr. Rahul Kushwah David Yu ▪ Experienced technology leader ▪ PhD, Banting Fellow ▪ Led multiple startups as CEO and ▪ Expertise in operations, business Director, driving operations, strategy and capital markets ▪ Led engineering teams at Four ▪ Develope
Slide 11: Advisory Board
Advisory Dr. Deepu Banerji MSc, PhD Dr. Navdeep Singh Nanda MBBS, MS, DNB Board ▪ Neurosurgeon with over 34 years’ experience in ▪ One of India’s leading thoracic surgeons, practicing in BLK microscopic and minimal invasive neurosurgery Super Speciality Hospital, the largest stand-alone private ▪ Su
Slide 12: Corporate Information and Contact
CSE : PMED OTCQB : PMEDF PR ED IC T ME DI X. C OM CORPORATE IN FORMAT ION 77 King Street West, Suite 3000 Toronto, ON, Canada M5K 2A1 CONTACT Rahul Kushwah COO – Predictmedix [email protected]
Predictmedix AI — Investor Presentation (February 2025) on 6ix